To the editor:
P-selectin glycoprotein ligand-1 inhibition blocks increased leukocyte-endothelial interactions associated with sickle cell disease in mice
Sickle cell disease (SCD) is a hemoglobinopathy caused by a single amino acid change in the ␤ globin subunit that predisposes hemoglobin to abnormal polymerization leading to stiff, sickled erythrocytes, and microvascular occlusions. 1 Although the vascular consequences of SCD are triggered by changes in the erythrocyte, 2 a chronic inflammatory state often ensues with many other cell types contributing to SCD pathology. For example, sickling of erythrocytes in the microvasculature is accompanied by increased platelet and leukocyte-endothelial (L-E) interactions that are strongly associated with vascular complications 3 including stroke, priapism, leg ulcers, and nephropathy. 4 Therapeutic targeting of molecules responsible for mediating these adhesive interactions has been shown to be potentially beneficial in preclinical models of SCD. 5 Inhibition of P-selectin in particular has been associated with reduced L-E interactions in mouse models of SCD. 6 The leukocyte ligand for P-selectin is P-selectin glycoprotein ligand-1 (Psgl-1), which also interacts with E-and L-selectin. Psgl-1 inhibition may be particularly effective in reducing adhesive interactions in SCD since Psgl-1-mediated signaling also affects activation of leukocytes, 7 which in turn affects adhesive properties of the endothelium. 8 To determine the effectiveness of Psgl-1 inhibition on reduction of L-E interactions in the microvasculature, we studied a humanized mouse model of SCD 9 treated with an anti-mouse Psgl-1 antibody. First, C57BL/6J mice underwent a bone marrow transplantation (BMT) procedure as previously described. 8 Recipient mice received bone marrow from wild-type donors (Hbb ϩ/ϩ ) or donors homozygous for the sickle cell mutation (Hbb h␤s/h␤s ). Eight weeks after BMT, mice receiving Hbb h␤s/h␤s marrow (n ϭ 10) were anemic compared with mice receiving Hbb ϩ/ϩ marrow (n ϭ 10; hematocrit -28.9 Ϯ 1.0 vs 36.7 Ϯ 0.8%, P Ͻ .0001), (hemoglobin -10.0 Ϯ 0.5 vs 12.3 Ϯ 0.4 g/dL, P Ͻ .001) and (RBC counts 7.5 Ϯ 0.5 vs 9.1 Ϯ 0.2 ϫ 10 6 /L, P Ͻ .01). Sickle-shaped erythrocytes were frequent in the peripheral blood smears of Hbb h␤s/h␤s mice and Hbb h␤s/h␤s mice exhibited a marked reticulocytosis compared with Hbb ϩ/ϩ mice (reticulocyte -30.2 Ϯ 4.4 vs 3.4 Ϯ 0.6% of RBCs, P Ͻ .00001). At the time of sacrifice (20 weeks after BMT), the average spleen size of Hbb h␤s/h␤s mice was 370.7 Ϯ 55.4 mg compared with 74.9 Ϯ 2.4 mg in Hbb ϩ/ϩ mice, P Ͻ .000001. At 16 weeks post BMT, mice were treated with weekly IV injection of anti-Psgl-1 antibody or control IgG antibody for 4 weeks. Intravital microscopy 8 was performed 20 weeks following BMT using intravenous rhodamine to label leukocytes. Leukocyte rolling and firm attachment were increased in Hbb h␤s/h␤s mice compared with Hbb ϩ/ϩ mice. However, anti-Psgl-1 treatment completely reversed the increased leukocyte rolling and firm attachment within the Hbb h␤s/h␤s mice. (Figure 1A-D) . Reduced L-E interactions were associated with reductions in levels of circulating soluble E-selectin (sE-sel), soluble P-selectin (sP-sel), and soluble vascular cell adhesion molecule 1(sVCAM-1; Figure 1G -I). Four weeks of treatment was sufficient to reduce iron deposition and necrotic areas of liver ( Figure 1L,O) . This was associated with reduced CD68 and TNF-␣ expression in the liver by RT-PCR ( Figure 1E-F) . In conclusion, inhibition of Psgl-1 may be an effective treatment for reducing vascular complications of SCD. 
